A mutant epidermal growth factor receptor (⌬EGFR) containing a deletion of 267 amino acids from the extracellular domain is common in human glioblastomas. We have previously shown that the mutant receptor fails to bind EGF, is constitutively phosphorylated, and confers upon U87MG glioblastoma cells expressing it (U87MG.⌬EGFR), an increased ability to form tumors in mice. Here we demonstrate that the constitutively phosphorylated ⌬EGFR enhances growth of glioblastoma cells through increased activity of Ras: 1) there was an increase in the proportion of Ras present in the GTPbound form, and 2) introduction of neutralizing anti-Ras 259 antibodies into U87MG and U87MG.⌬EGFR cells by microinjection inhibited DNA synthesis to the same low level in both cell populations. We also show that the truncated EGF receptor constitutively associates with the adapter proteins Shc and Grb2 which are involved in the recruitment of Ras to activated receptors. Several derivatives of ⌬EGFR containing single, or multiple mutations at critical autophosphorylation sites were constructed and used to demonstrate that the major Shc binding site is Tyr-1148, and that Grb2 association occurs primarily through Tyr-1068. We conclude that the increased tumorigenic potential of glioblastoma cells expressing the truncated EGF receptor is due at least in part to Ras activation presumably involving the Shc and Grb2 adapter proteins.
The EGF 1 receptor family of tyrosine kinases has been implicated in a wide variety of human tumors, where they are typically overexpressed by gene amplification or increased transcription (1) . In glioblastoma, deletions in the EGF receptor gene are also found at high frequency. The most common deletion involves exons 2 through 7 and occurs in about 10 -20% of these tumors. The potential importance of this deleted receptor is underscored by its recent detection in tumors of the breast and lung (2) (3) (4) (5) . Thus, it appears that overexpression of an EGF receptor which cannot bind its ligand is advantageous to tumor growth. We (6) and others (7) (8) (9) (10) have demonstrated that when this deletion mutant of EGF receptor (de 2-7 EGFR, here called ⌬EGFR) is overexpressed in U87MG glioblastoma cells, NIH 3T3 fibroblasts, or Chinese hamster ovary cells it becomes phosphorylated on tyrosine residues, although the extent of phosphorylation is less than that observed for acutely EGF-stimulated full-length receptor. Thus, it would appear that either a small number of receptors become fully phosphorylated, or that a large number of receptors are phosphorylated, but at low stoichiometry. In any case, this constitutive phosphorylation is associated with the ability of the mutant receptor to confer sustained enhancement of the tumorigenic capacity of U87MG glioblastoma cells (6) .
A great deal of progress has been made recently in understanding the mechanisms by which tyrosine kinase receptors signal. Following ligand binding, receptors dimerize and become phosphorylated on tyrosine residues which act as docking sites for proteins containing phosphotyrosine binding domains (11) . Two such domains have been identified, the SH2 (Src homology 2) domain and the PTB (phosphotyrosine-binding domain) (12) also termed the phosphotyrosine interaction domain (13) . Many proteins which interact with the EGF receptor contain SH2 domains including Shc, Grb2, phospholipase C-␥, GAP, STAT 1␣, STAT 3, and phophotyrosine phosphatase SH-PTP2. The Shc adapter protein also contains a PTB which appears to be responsible for its major interaction at tyrosine 1148 (14) . Both Shc and Grb2 have been shown to be important for recruitment of Ras to activated receptors. Grb2 can bind directly to phosphotyrosines present in the consensus sequence YLN or indirectly through phosphorylated Shc (15, 16) . One of the SH3 domains of Grb2 associates with the nucleotide exchange factor for Ras, Sos (17, 18) , thereby promoting increased Ras activation which initiates a cascade of activation of serine/ threonine kinases and ultimately to an increase in gene transcription in the nucleus.
Since Ras is a key component of mitogenic signaling pathways, we sought to determine whether it is responsible for the increased tumorigenicity of U87MG.⌬EGFR cells. Here we demonstrate by measurement of the concentration of GTPbound Ras, that it is indeed activated in the U87MG.⌬EGFR cells relative to the parental U87MG cells. Moreover, inhibition of Ras function by microinjection of a neutralizing antibody into U87MG and U87MG.⌬EGFR cells reduces DNA synthesis to the same low background level suggesting that Ras plays a role in the increased replication of cells expressing the ⌬EGFR. We also demonstrate that both Grb2 and Shc constitutively interact with the phosphorylated ⌬EGF receptor expressed in U87MG.⌬EGFR cells, in a similar manner to wild-type EGF receptor, thereby providing a potential mechanism for the activation of Ras. Together these results suggest that Shc, Grb2, and Ras are involved in the enhanced mitogenesis and tumor forming potential of cells expressing the ⌬EGF receptor.
EXPERIMENTAL PROCEDURES

Construction and Production of Mutant EGFR Retroviral Vectors-
The ⌬EGFR construct (de 2-7 EGFR) was described previously (6) . Phosphorylation site point mutants illustrated in Fig. 2A were constructed by replacing restriction fragments of the ⌬EGFR construct with those from mutant EGF receptor clones kindly provided by G. N. Gill, University of California, San Diego, or by site-directed mutagenesis, and will be described in detail elsewhere. A mutant encoding a lysine 721 to methionine replacement at the ATP binding site (DK) was also constructed. Mutant receptors were initially constructed in pBluescript SK(Ϫ) vector for sequence analysis and transferred to the retroviral vector, pLRNL (19) for production of viral stocks as described previously (6) .
Isolation of U87MG Cell Populations Expressing High Levels of Mutant ⌬EGFR-U87MG cells were infected with virus, and populations expressing similar high levels of the point-mutant truncated EGF receptors were selected by fluorescence-activated cell sorting analysis as described previously (6) .
Determination of Percentage of Ras Present in the GTP-bound (Active)
State-Extracts were prepared from U87MG cells, and U87MG.⌬EGFR cells, which had been incubated in serum-free medium for 32-48 h prior to lysis. Measurement of Ras GTP levels was performed essentially as described previously (20) , except that the initial Sephadex column purification step was omitted.
Microinjection of 259 Anti-Ras Antibody into U87MG and U87MG. ⌬EGFR Cells-U87MG and U87MG.⌬EGFR cells were plated on coverslips at a density of 1000 cells/mm 2 , and cultured for 24 h in Dulbecco's modified Eagle's medium, 10% fetal bovine serum. Cells were washed in phosphate-buffered saline and cultured for 8 h in Dulbecco's modified Eagle's medium without serum. Cells were then microinjected with 259 anti-Ras antibody (2.5 mg/ml) (21) together with Guinea pig IgG (12 mg/ml) to facilitate detection of injected cells, or with control rat antibody (12 mg/ml) as described previously (22) . Starvation was continued for a further 16 h. Cells were then incubated with BrdUrd in fresh Dulbecco's modified Eagle's medium without serum for 24 h, when they were fixed and stained as described previously (22) using a mouse monoclonal anti-BrdUrd antibody (Amersham) and a rhodamine-conjugated goat anti-mouse IgG (Jackson Immunoresearch Laboratories). Microinjected cells were visualized with a fluorescein-conjugated antiguinea pig IgG antibody (Jackson Immunoresearch Laboratories).
Immunoprecipitation and Western Blotting-Immunoprecipitations were generally performed from total cell lysate containing 0.75 mg of protein as described previously (23) using 2.5 g of antibody bound to Protein A-Sepharose. Immunoprecipitates were analyzed on Tricine gels (24) and immunoblots were performed, using the ECL chemiluminescent detection protocol (Amersham). Where whole lysates were analyzed, 75 g of total protein was loaded per lane. In cases where EGF stimulation was required, cells were treated with 10 Ϫ7 M EGF for 5 min prior to lysis. Antibodies against Shc, Grb2, and phosphotyrosine (Rc20) were from Transduction Laboratories (catalog numbers: S14630, G16720, E120H, respectively). The monoclonal antibody used for specific precipitation of the truncated EGF receptor was raised against cells expressing the truncated EGFR and will be described elsewhere, 2 and the antibody for precipitation of endogenous receptor was EGFR1 (Santa Cruz, sc-101). A monclonal antibody, C13 used for detection of both wild-type and truncated EGFR on immunoblots was generously provided by G. N. Gill, University of California, San Diego. In cases where a rabbit anti-EGFR antibody was required for immunoblotting, the polyclonal antibody 12E (25) was kindly provided by W. J. Gullick, ICRF, London.
Precipitation of Truncated EGF Receptor Using GST Fusion Proteins of Shc Fragments-The GST-SH2 and GST-NCH constructs were kindly provided by K. Ravichandran (Dana-Faber Cancer Institute, Harvard Medical School) and were described previously (26) . Fusion proteins were prepared, and precipitations were performed using 10 g of fusion protein and 1.5 mg of total protein per precipitation as described elsewhere (27) .
RESULTS
Ras Is Activated in U87MG.⌬EGFR Cells Relative to U87MG
Cells-In order to establish a role for Ras in the enhanced proliferation of U87MG.⌬EGFR cells, measurement of Ras GTP levels was performed on cells which had been grown in the absence of serum for 32-48 h. The number of femtomoles of GTP, and GDP bound to Ras, was determined per mg of protein in three independent experiments, measurements being performed in duplicate. The values obtained for GTP and GDPbound Ras precipitated from U87MG cells were 102 Ϯ 24.7 and 1424 Ϯ 77.0 fmol/mg protein, respectively; for U87MG.⌬EGFR the corresponding values were 172 Ϯ 22.3 and 1250 Ϯ 115 fmol/mg protein. The differences observed for GTP-bound Ras between the two cell types were significantly different (p Ͻ 0.01), as determined by paired Student's t test analysis. Thus 12.1% of the Ras precipitated from U87MG.⌬EGFR cells grown in the absence of serum was present in the GTP-bound, active form, compared to 6.7% of Ras precipitated from the U87MG parental cells starved for the same length of time (Fig. 1A) . We observed no difference in Ras GTP levels whether cells were starved for 32 or 48 h.
Inhibition of Ras function in U87MG and U87MG.⌬EGFR Cells-Since Ras was activated in the U87MG.⌬EGFR cells relative to the parental U87MG cells we were interested to determine whether inhibition of Ras function in these cells would diminish the observed growth advantage. A presumed excess of inhibitory anti-Ras 259 antibodies was therefore introduced into the cells by microinjection (Fig. 1B) , and DNA synthesis was measured by BrdUrd incorporation. The percentage of injected cells incorporating BrdUrd was calculated for cells injected with anti-Ras 259 antibody and control rat IgG. These values were compared with the percentage BrdUrd incorporation of uninjected cells. The data illustrated in Fig. 1B represents the mean of 3-9 individual experiments. Under the starvation conditions used, approximately 50% of uninjected U87MG.⌬EGFR cells underwent DNA synthesis as compared to 21% of parental U87MG cells. Injection of control rat IgG into these cells had no significant effect on the observed values (50 and 28%, respectively, for control IgG injection of U87MG. ⌬EGFR cells and U87MG cells). Injection of 259 antibody into both U87MG.⌬EGFR and U87MG cells almost completely abolished BrdUrd incorporation to 3.4 and 1.7%, respectively. These values were not significantly different. Thus, it would appear Ras activation is required for DNA synthesis in the parental U87 cells, and that the additional DNA synthesis observed in the U87MG.⌬EGFR cells is also dependent on Ras activity.
Phosphorylation of ⌬EGFR Point Mutants and Co-precipitation with Anti-Shc Antibody-The various phosphorylation site mutants of ⌬EGFR which were expressed in U87MG cells are illustrated in Fig. 2A . Initial studies were performed on ⌬EGFR, the kinase-impaired mutant, DK, and point mutants DY1, DY2, DY3, and DY5. Immunoblotting of whole cell lysates prepared from each of the cell populations expressing mutant receptors with an anti-EGFR antibody demonstrated that the cells expressed approximately equal amounts of the various receptors (Fig. 2B, a) . Analysis of the same immunoblots with an anti-phosphotyrosine antibody revealed that little or no phosphorylation of the DK mutant could be detected. DY1 and DY2 reproducibly showed levels of phosphorylation approximately 2-fold less than that of ⌬EGFR (Fig. 2B, b) . Very little phosphorylation for DY3 or DY5 was observed in whole cell lysates, although a small amount of phosphorylation could be detected on both DY3 and DY5 if these receptors were first immunoprecipitated using an antibody specific for the truncated receptor (data not shown). A number of proteins of ap-proximate molecular mass 120, 90, and 55 kDa were phosphorylated in response to EGF treatment, which were also phosphorylated in the absence of EGF in cells expressing the ⌬EGFR.
In order to test whether the ⌬EGFR, and any of the point mutants were associated with the adapter protein Shc, we co-precipitated receptor mutants using an anti-Shc antibody. For comparison, Shc was precipitated from EGF-treated cells to confirm the association between phosphorylated endogenous receptor and Shc. Immunoprecipitates were subjected to SDSpolyacrylamide gel electrophoresis and proteins transferred to nitrocellulose for analysis with anti-EGFR and anti-phosphotyrosine antibodies. Using anti-EGFR antibody, C13, we were able to detect the weak presence of ⌬EGFR in Shc immunoprecipitates (data not shown), however, using the more sensitive anti-phosphotyrosine antibody, Rc20, we reproducibly detected a phosphoprotein of 145 kDa which co-migrated with the ⌬EGFR (Fig. 2B, c) . We also found that phosphoproteins corresponding to DY1 and DY2 co-precipitated with Shc. It was not possible to draw any conclusions about the association of DK, DY3, and DY5 since we were dependent on the presence of phosphotyrosine for protein detection, and these mutants did not phosphorylate appreciably. Thus, we conclude that ⌬EGFR and the DY1 and DY2 mutants constitutively associate with Shc when expressed in glioblastoma cells.
Phosphorylation of Shc and Association with Grb2-Since ⌬EGFR and the DY1 and DY2 mutants appeared to associate 
FIG. 2. Interaction of phosphoproteins with Shc in U87MG cells expressing mutant EGFRs.
A, all mutants analyzed contained a truncation of 801 base pairs in the EGFR extracellular domain. The ⌬ (⌬EGFR) mutant contained intact phosphorylation sites; DK contained a lysine to methionine point mutation at the ATP binding site (K721); DY1, DY2, DY3, DY4, and DY5 contained tyrosine to phenylalanine substitutions at known phosphorylation sites as indicated, where X denotes a mutated site. B, lysates prepared from EGF stimulated (ϩ) and unstimulated (Ϫ) U87MG cells expressing truncated EGFR mutants were analyzed for the presence of the truncated receptors (a) and for the presence of tyrosine-phosphorylated proteins (b). Shc immunoprecipitates prepared from these cells were probed with an anti-phosphotyrosine antibody to detect the presence of phosphorylated mutant EGF receptors (c), and phosphorylated Shc (d). Shc precipitates were also analyzed for the presence of Grb2 associated with Shc (e) with Shc, we determined whether the phosphorylation state of Shc correlated with the expression of particular ⌬EGFR mutants, and whether phosphorylated Shc was associated with Grb2 in the cells expressing the ⌬EGFR mutants. Shc protein was precipitated from EGF stimulated and unstimulated U87MG cells, and cells overexpressing the mutant EGFR constructs (⌬EGFR, DK, DY1, DY2, DY3, and DY5) essentially as described above, except that products were resolved on 12% Tricine gels to favor resolution of proteins less than 100 kDa, and that electrotransfer was performed for a shorter time. Immunoblots were probed with antibodies recognizing antiphosphotyrosine and Grb2 (Fig. 2B, d and e) . EGF stimulation demonstrated that all three isoforms of Shc (p66, p52, and p46) were phosphorylated in response to activation of the endogenous wild-type EGFR in each cell type. Shc protein precipitated from U87MG cells expressing ⌬EGFR, DY1, and DY2 without EGF stimulation was phosphorylated to a greater extent than that precipitated from DK cells which was essentially unphosphorylated and comparable to that precipitated from the unstimulated parental U87MG cell line. Cells expressing DY3 and DY5 appeared to show an intermediate level of phosphorylation even though Shc was unable to form a stable complex with these receptors (Fig. 3c) . Reprobing of the same immunoblots with an anti-Grb2 antibody demonstrated that in each case where Shc was phosphorylated, Grb2 was found associated with the complex (Fig. 2B, e) . Thus it appears that Shc phosphorylation is dependent on the kinase activity of ⌬EGFR, and that Shc phosphorylation is most efficient in the cells expressing mutant receptors which can bind Shc, although mutant receptors which cannot bind Shc appear to permit a small degree of Shc phosphorylation. We would predict that phosphorylation of Shc would permit its association with Grb2, and indeed this appears to be the case since Grb2 was found associated with Shc in all cases where we could detect its phosphorylation.
Association of Shc and Grb2 with ⌬EGFR-Since our coprecipitation data with the anti-Shc antibody depended on the presence of phosphotyrosine for detection of truncated EGF receptor, we sought to demonstrate that the same association of Shc with ⌬EGFR could be detected when precipitations were performed in the inverse orientation with an antibody specifically recognizing ⌬EGFR and its derivatives. 2 In these experiments, an additional mutant, DY4, was also analyzed (as illustrated in Fig. 2A ). Shc association with EGF-stimulated wild-type receptor was examined for comparison. In this case, precipitations were performed with the EGFR1 monoclonal antibody. The results of these studies are illustrated in Fig. 3 . The precipitates of wild-type receptor from the U87MG.wtEGFR cells contained less receptor than precipitates from cells expressing the truncated receptor mutants, as they were performed using lysate prepared from one-third of the number of cells (Fig. 3a) . In this particular experiment less of the DK mutant protein was present in precipitates as compared to the other truncated mutants (Fig. 3a) ; however, in other experiments we have not been able to detect significant association of Shc with the kinase-inactive mutant. The phosphorylation pattern of the mutant receptors present in immunoprecipitates is consistent with that illustrated in Fig. 2B ; however, mutant DY4 and EGF stimulated full-length EGFR are shown for comparison (Fig. 3b) . Shc protein was found to be associated with ⌬EGFR, DY1, and DY2 in approximately equal amounts (Fig. 3c) . A small amount of Shc associated with DY4 but Shc did not specifically bind to DY3 and DY5. These findings are consistent with the data for the full-length EGF receptor where Tyr-1148 has been demonstrated to be the major Shc binding site in cells. However, a small amount also appears to bind through Tyr-1173.
In order to determine whether Grb2 was similarly associated with the ⌬EGFR, blots were reprobed with an antibody recognizing Grb2 (Fig. 3d) . In this case Grb2 was found to be mainly associated with the full-length receptor, ⌬EGFR and DY1 only. This is consistent with previous reports indicating that the major Grb2 binding site on EGF receptor is Tyr-1068. Therefore, it appears that the ⌬EGFR behaves like wild-type EGF receptor with respect to its ability to associate with Shc and Grb2.
In Vitro Binding of ⌬EGFR Mutants to GST Fusion Proteins of the Shc-SH2 and PTB-Given the difference in the ability of Shc to bind various point mutants in cells we were interested to determine which domains of Shc were responsible for association with the different sites. Fusion proteins encompassing the SH2 domain of Shc (GST-SH2) and the PTB and collagen homology domain combined (GST-NCH) were used to precipitate receptor species from the U87MG cells expressing various point mutated ⌬EGFRs. Lysates were analyzed by immunoblotting to confirm that similar amounts of truncated receptor were present in each case (data not shown). Probing of immunoblots prepared from these precipitates with an anti-EGFR antibody demonstrated that ⌬EGFR, and the DY1, DY2, and DY4 mutants were all able to associate with the Shc-PTB in vitro, whereas DY3 and DY5 were unable to bind (Fig. 4a) . Probing of the same immunoblots with an anti-phosphotyrosine antibody gave the same result (Fig. 4b) . We were unable to detect binding of the EGFR mutants to the SH2 domain with
FIG. 3. Interaction of Shc and Grb2 with truncated EGFR mutants.
Lysates were prepared from U87MG cells expressing truncated receptor mutants, and U87MG cells expressing wild-type EGFR (U87MG.wtEGFR), which had been pretreated with EGF (ϩ) or were untreated (Ϫ). Total lysate was analyzed to demonstrate the difference in phosphorylation state of the receptor mutants (b). Truncated EGFR was precipitated from equal amounts of total protein using an antibody specific for the mutant receptor, except in the case of the U87MG.wtEGFR cells where an antibody recognizing the full-length receptor was used. Immunoprecipitates were analyzed for EGFR (a) Shc (c) and Grb2 (d) by Western blotting.
the C13 anti-EGFR antibody (Fig. 4a) . This was not surprising since we have previously shown that precipitation of full-length receptor with the SH2 domain fusion protein is much less efficient than precipitation with fusion proteins containing the PTB (25) . However, probing of the same immunoblots with the more sensitive anti-phosphotyrosine antibody demonstrated that whereas a phosphoprotein corresponding to ⌬EGFR and DY4 were able to bind equally well to the Shc-SH2 domain, no such binding was observed for DY1 and DY2. A rabbit polyclonal anti-EGFR antibody was able to weakly detect the bound ⌬EGFR and DY4 (data not shown). A number of other phosphoproteins present in the cell lysates were also found to bind the Shc-SH2 domain, most notably a protein of approximately 130 kDa, the binding of which appeared to be somewhat reduced in the U87MG.⌬EGFR cells. Thus, although a number of the point mutated ⌬EGFRs (DY1, DY2, and DY4) are able to potentially associate with Shc through its PTB, the only point mutant which retains the ability to associate with the SH2 domain is DY4.
DISCUSSION
The first transforming mutant EGFR to be identified was the product of the avian erythroblastosis virus v-erbB gene which encodes an EGFR with N-and C-terminal truncations as well as point mutations. Removal of the extracellular domain of EGFR has been shown to result in a weak but constitutive oncogenic activation of the receptor, while ligand binding to the full-length receptor results in a much stronger, EGF-dependent activation (28) . Consistent with these observations, the v-erbB, which encodes an EGF receptor displays much weaker tyrosine kinase activity than that of ligand activated wild-type receptor. A mutation involving deletion of 801 base pairs of the EGFR gene encoding a portion of the extracellular domain has been observed in human tumors of the brain, breast, and lung (2) (3) (4) (5) . This mutant receptor displays low level ligand independent phosphorylation in NIH 3T3 cells, NR6, Chinese hamster ovary, or U87MG glioblastoma cells. We have used the U87MG cell line as the host for the expression of the mutant receptor since the ⌬EGFR mutation spontaneously occurs in this type of cell in vivo. Expression of ⌬EGFR in these cells promotes tumor formation in mouse brain (6) , and results in increased DNA synthesis of serum-starved cells. Here we have investigated the possible signaling pathways which may contribute to the increased tumorigenic properties of cells expressing the truncated EGFR.
Recent studies have pointed to a key role for Ras in signaling pathways downstream of most receptors including tyrosine kinases, heterotrimeric G-protein-coupled receptors, and cytokine receptors (29) . Moreover, it appears that the adapter proteins Shc and/or Grb2 are almost universally involved in the initial recruitment of the exchange factor for Ras to activated receptors. It was therefore the objective of this study to determine whether these key elements of the normal EGFR signaling pathway played a role in the enhanced DNA synthesis and tumorigenesis in U87MG cells overexpressing the ⌬EGFR.
U87MG.⌬EGFR cells were shown to possess an approximately 2-fold increase in the proportion of Ras in its active GTP-bound form relative to the parental U87MG cells. Under the starvation conditions described these cells also showed a 2-fold increase in DNA synthesis which could be abolished by the introduction of an inhibitory Ras antibody into the cells. These data illustrate that the enhanced growth of U87MG.⌬EGFR cells is dependent on Ras activity. This is supported by a recent study in which expression of the ⌬EGFR in NIH 3T3 cells was shown to promote modest activation of elements of the mitogen-activated protein kinase cascade (30) . Whether this activation of the Ras pathway is primarily responsible for enhanced tumorigenesis remains to be determined.
We have also demonstrated that the truncated receptor behaves like the full-length wild-type receptor with respect to its interaction with Shc and Grb2, and binds to both in an unregulated, ligand-independent fashion when expressed in U87MG cells. The major sites of phosphorylation were tyrosines 1068, 1148, and 1173, as has been shown for the full-length receptor. A low level of phosphorylation of a mutant receptor containing only sites Tyr-992 and Tyr-1086 was detectable by anti-phosphotyrosine immunoblotting if the receptor was first precipitated with an anti-EGFR antibody; however, a similar low level of phosphorylation was also detectable on a receptor lacking all five of the major phosphorylation sites. Grb2 only bound appreciably to constructs containing intact Tyr-1068, and Shc only bound efficiently in cells to those with intact Tyr-1148, although a small amount bound to a mutant with only intact Tyr-1173, consistent with findings for the full-length receptor (14, 31, 32) .
In vitro experiments using GST constructs of Shc domains demonstrated that the SH2 domain of Shc can bind only to Tyr-1173 of the truncated receptor, whereas its PTB binds to Tyr-1148 or Tyr-1173 in vitro. Tyr-1148 is contained within an NPXY motif which has been demonstrated to be the consensus required for the Shc-PTB (12, 27, 33) . Tyr-1173 is contained within the motif NAXYLRV which contains an imperfect NAXY binding motif for the PTB, and a motif which binds the Shc-SH2 domain (Y-hydrophobic-X-hydrophobic) (34) C-terminal to the phosphotyrosine. Given association data in cells, it would appear that the primary interaction site is through Tyr-1148, however, binding of the Shc-PTB to Tyr-1148 could promote a secondary binding to the same or adjacent receptor through its SH2 domain. Interestingly, U87MG cells expressing the DY1 mutant (which only lacks Tyr-1173) form tumors in animals at a similar rate to the parental cell line, suggesting that inter- FIG. 4 . Association of mutant EGFRs with GST fusion proteins of Shc-SH2 and PTB. GST fusion proteins containing the Shc-SH2 (SH2) and PTB (NCH) domains were used to precipitate truncated EGFR point mutants from U87MG cells in which they were expressed. Precipitates were analyzed by SDS-polyacrylamide gel electrophoresis and immunoblotting with antibodies recognizing EGFR (a) or phosphotyrosine (b). Immunoblots from NCH precipitates probed with either anti-EGFR or anti-PY antibody were exposed to autoradiography film for 15 s. Immunoblots from SH2 precipitates probed with anti-EGFR antibody were exposed for 15 s, and those probed with anti-phosphotyrosine were exposed for 1 min.
actions with this site are essential for promoting tumor growth. 3 One such interaction might be with the Shc-SH2 domain since the DY1 mutant is incapable of binding to Shc-SH2 as we have demonstrated in vitro. A mutant which only contains Tyr-1173 (DY4) also has impaired tumor promoting properties, suggesting that this site is required in addition to others to provide interactions necessary to provide a growth advantage. Thus binding of Shc through both SH2 and PTB may be necessary in order to promote associations which are necessary for DNA synthesis or tumorigenesis, which may not represent the same phenomenon. In support of this notion, microinjection of the Shc-SH2 domain into NIH 3T3 cells overexpressing full-length EGFR suppressed EGF-induced DNA synthesis indicating that interactions with this domain as well as with the PTB are important for mitogenesis (35) . Perhaps a binding site for a novel protein remains buried unless the PTB and SH2 domains are occupied. A number of proteins have been shown to associate with Shc in response to various stimuli, in addition to Grb2 (36 -39) . Alternatively, Shc could be involved in bridging two adjacent receptors. This may be of more importance to truncated receptors than full-length receptors which dimerize inefficiently in the absence of a ligand binding domain. In the case of the full-length EGFR it has been reported that elimination of individual phosphorylation sites did not significantly affect the kinase activity or mitogenic properties of the receptor (8, 40, 41) . This apparent discrepancy may be explained by ability of the full-length receptor to heterodimerize and signal through related receptors.
The observation that mutant receptors lacking all Shc-binding sites were able to phosphorylate Shc to some extent is also noteworthy. This phenomenon has also been observed for fulllength EGFR and c-erbB-2 species lacking phosphorylation sites (42) (43) (44) (45) . Shc phosphorylation was greater, and therefore more efficient for those mutants which were still able to bind Shc. It is possible that the large number of truncated receptors on the surface of the cell simply encounter Shc molecules bound to lipids on the inside of the membrane and phosphorylate these at low frequency. In all cases where Shc was phosphorylated it also bound Grb2 creating complexes which could presumably signal to Ras, albeit the localization of the active complexes was not determined. The majority of Grb2 associated with the receptor, however, appeared to be bound directly to Tyr-1068 since DY1 appeared to bind almost as much Grb2 as the ⌬EGFR, but DY2 did not bind as efficiently. Thus, it is possible that the Shc bound to Tyr-1148 and -1173 is eliciting additional interactions which may not involve Grb2 and may or may not be upstream of Ras.
One key question which remains to be determined is why the mutant EGF receptors are selected for loss of this specific portion of the extracellular domain. One possibility may lie in the observation that truncation results in a modest increase in autophosphorylation relative to the full-length receptor, this phosphorylation occurring at the same major sites, enabling the truncated receptor to form the same interactions as the wild-type receptor. Whether or not this explains why the removal of the ligand-binding domain should provide such a significant growth advantage is yet unclear. Our recent work suggests that a deficiency in internalization may also be an important feature of the growth stimulatory activity of this mutant receptor. 3 Signalling from the wild-type receptor is initiated by EGF binding and the response is complex, being regulated by protein kinase C, internalization, and dephosphorylation. In addition, full-length receptors can heterodimerize with other family members which could potentially sustain a differentiation response and not promote cell division (46) . The extracellular domain may also interact with other surface molecules on adjacent cells such as heparin-binding EGF which could reduce the invasiveness of the cells (47) . Perhaps the elimination of the EGF binding element eliminates potential effectors from the repertoire of the truncated receptor leaving those which are of advantage for cell division.
